JP2025507971A - 前立腺特異的膜抗原を標的とする放射性標識化合物 - Google Patents

前立腺特異的膜抗原を標的とする放射性標識化合物 Download PDF

Info

Publication number
JP2025507971A
JP2025507971A JP2024552478A JP2024552478A JP2025507971A JP 2025507971 A JP2025507971 A JP 2025507971A JP 2024552478 A JP2024552478 A JP 2024552478A JP 2024552478 A JP2024552478 A JP 2024552478A JP 2025507971 A JP2025507971 A JP 2025507971A
Authority
JP
Japan
Prior art keywords
compound
independently
optionally
methyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507971A5 (https=
Inventor
リン，クオ－シュヤン
ベナール，フランソワ
ジャン，チョンチョン
ジャン，ジョンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2025507971A publication Critical patent/JP2025507971A/ja
Publication of JP2025507971A5 publication Critical patent/JP2025507971A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024552478A 2022-03-04 2023-03-03 前立腺特異的膜抗原を標的とする放射性標識化合物 Pending JP2025507971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316595P 2022-03-04 2022-03-04
US63/316,595 2022-03-04
PCT/CA2023/050280 WO2023164775A1 (en) 2022-03-04 2023-03-03 Radiolabeled compounds targetng the prostate-specific membrane antigen

Publications (2)

Publication Number Publication Date
JP2025507971A true JP2025507971A (ja) 2025-03-21
JP2025507971A5 JP2025507971A5 (https=) 2026-03-10

Family

ID=87882764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552478A Pending JP2025507971A (ja) 2022-03-04 2023-03-03 前立腺特異的膜抗原を標的とする放射性標識化合物

Country Status (6)

Country Link
US (1) US20250186627A1 (https=)
EP (1) EP4486756A1 (https=)
JP (1) JP2025507971A (https=)
AU (1) AU2023226956A1 (https=)
CA (1) CA3244865A1 (https=)
WO (1) WO2023164775A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020257786B2 (en) 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CN121773094A (zh) * 2023-09-12 2026-03-31 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
CN120202191A (zh) * 2023-09-12 2025-06-24 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
BR112021025810A2 (pt) * 2019-06-21 2022-05-10 Provincial Health Services Authority Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
US11850291B2 (en) * 2019-10-25 2023-12-26 National Atomic Research Institute PSMA targeted radiotherapy medicine and preparation method thereof

Also Published As

Publication number Publication date
AU2023226956A1 (en) 2024-09-12
US20250186627A1 (en) 2025-06-12
CA3244865A1 (en) 2023-09-07
EP4486756A1 (en) 2025-01-08
WO2023164775A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7618599B2 (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP2025507971A (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
AU2019273132B2 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
CA3248367A1 (en) Radiolabeled compounds for imaging fibroblast-activating protein (FAP) and treating FAP-related disorders
US20240018110A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
JP2025513489A (ja) Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
US20260077073A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
BR122025011654A2 (pt) Compostos radiomarcados de direcionamento de antígeno de membrana específico da próstata, seus usos, composição e método de imageamento

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260302